TJE, T., A, D., S, S., & M, L. (2021). Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press.
Style de citation Chicago (17e éd.)TJE, Tarigan, Dwijayanti A, Setyowati S, et Louisa M. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin Versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press, 2021.
Style de citation MLA (8e éd.)TJE, Tarigan, et al. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin Versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.